elbion and Wyeth Enter Collaboration to Develop New Treatments for Schizophrenia
The agreement includes an upfront payment, milestones and research funding potentially totalling up to $110 million over the life of the agreement. Wyeth will also pay elbion royalties on worldwide annual net sales of products developed under the agreement.
PDE 10 is highly expressed in the neurons in the brain associated with neurological and psychiatric disorders including schizophrenia and psychosis. By inhibiting PDE10 activity it is thought that the function of neurons could be improved offering a new mechanism of action for the treatment of schizophrenia, an area of high unmet medical need, and also for other neurological conditions.
elbion and Wyeth will develop new chemical entities for the inhibition of PDE10 drawing on elbion's tremendous expertise in developing new leads and compounds for PDE targets. Wyeth will be responsible for further clinical development of selected compounds. The research work supporting the collaboration will be carried out at elbion's R&D facility at Radebeul, Germany and also involve scientists at elbion's headquarters in Leuven.
Most read news
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.